Avantor, Inc. (NYSE:AVTR) EVP James Bramwell sold 2,505 shares of the company’s stock in a transaction on Monday, January 11th. The stock was sold at an average price of $30.00, for a total value of $75,150.00. Following the transaction, the executive vice president now directly owns 394,847 shares in the company, valued at $11,845,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

James Bramwell also recently made the following trade(s):

  • On Monday, December 21st, James Bramwell sold 10,020 shares of Avantor stock. The stock was sold at an average price of $27.14, for a total value of $271,942.80.

Shares of AVTR opened at $29.20 on Thursday. The business’s 50-day moving average is $27.51 and its two-hundred day moving average is $23.51. The company has a market capitalization of $16.88 billion, a P/E ratio of 243.33, a P/E/G ratio of 1.08 and a beta of 1.84. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.38 and a current ratio of 2.02. Avantor, Inc. has a fifty-two week low of $6.66 and a fifty-two week high of $30.73.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.03. Avantor had a return on equity of 33.44% and a net margin of 2.21%. The company had revenue of $1.61 billion for the quarter. Analysts forecast that Avantor, Inc. will post 0.84 EPS for the current year.

A number of brokerages have recently issued reports on AVTR. KeyCorp raised Avantor from a “sector weight” rating to an “overweight” rating and set a $33.00 price target on the stock in a research report on Monday, November 9th. Morgan Stanley upped their target price on Avantor from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, October 29th. Raymond James upped their target price on Avantor from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday. Wells Fargo & Company upped their target price on Avantor from $23.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Finally, Robert W. Baird upped their target price on Avantor from $23.00 to $27.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $26.08.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Avantor by 14.4% during the 3rd quarter. BlackRock Inc. now owns 29,767,829 shares of the company’s stock worth $669,478,000 after acquiring an additional 3,757,281 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Avantor by 33.8% during the 3rd quarter. Nuveen Asset Management LLC now owns 25,200,588 shares of the company’s stock worth $566,761,000 after acquiring an additional 6,370,236 shares in the last quarter. Boston Partners boosted its stake in shares of Avantor by 9.0% during the 3rd quarter. Boston Partners now owns 19,005,381 shares of the company’s stock worth $427,430,000 after acquiring an additional 1,569,620 shares in the last quarter. State Street Corp boosted its stake in shares of Avantor by 13.2% during the 3rd quarter. State Street Corp now owns 8,551,903 shares of the company’s stock worth $192,332,000 after acquiring an additional 994,415 shares in the last quarter. Finally, Natixis boosted its stake in shares of Avantor by 52.0% during the 3rd quarter. Natixis now owns 5,837,646 shares of the company’s stock worth $131,289,000 after acquiring an additional 1,997,944 shares in the last quarter. 84.79% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc provides products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries worldwide. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits.

Recommended Story: What is the price-sales ratio?

Insider Buying and Selling by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.